Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349253 | 1.00 | LMNA (0.70) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL2776182 | 1.00 | LMNA (0.70) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL2774718 | 0.91 | LMNA (0.72) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL2778969 | 0.86 | LMNA (0.65) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046076 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12018219 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL977919 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046078 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL14031844 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12232219 | 0.83 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081946-B1 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | CBT DEV LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | LMNA 3103/4885NT5E 3242/4885HIF1A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.